Phathom Pharmaceuticals Earnings Review: Q4 Summary
Benzinga Insights 8 months ago
Earnings
The earnings results for Phathom Pharmaceuticals (NASDAQ:PHAT) for Q4 were made public on Thursday, February 26, 2026 at 07:00 AM.
Here's a comprehensive overview of the announcement.
Earnings
Phathom Pharmaceuticals beat estimated earnings by 57.89%, reporting an EPS of $-0.08 versus an estimate of $-0.19.
Revenue was up $27.92 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.26 which was followed by a 1.8% increase in the share price the next day.
Here's a look at Phathom Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.41 | -0.88 | -1.07 | -1.08 |
| EPS Actual | -0.15 | -0.79 | -1.07 | -0.79 |
| Revenue Estimate | 47.87M | 35.85M | 29.02M | 25.65M |
| Revenue Actual | 49.50M | 39.50M | 28.52M | 29.66M |
To track all earnings releases for Phathom Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.